StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.44+0.03 (+2.13%)

Close on Nov 18, 2026Market cap $14.32MP/E –Yield –

Seres Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Seres Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$51.26M. For fiscal 2025 it was $1.12M. The highest annual figure on record is $43.92M in fiscal 2016.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.12M–
FY2024Dec 31, 2024-$148.61M–
FY2023Dec 31, 2023-$117.35M–
FY2022Dec 31, 2022-$228.82M-3521.3%
FY2021Dec 31, 2021$6.69M–
FY2020Dec 31, 2020-$93.61M–
FY2019Dec 31, 2019-$76.52M–
FY2018Dec 31, 2018-$62.85M–
FY2017Dec 31, 2017-$75.52M-272.0%
FY2016Dec 31, 2016$43.92M–
FY2015Dec 31, 2015-$40.84M–
FY2014Dec 31, 2014-$10.36M–
FY2013Dec 31, 2013-$5.32M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$22.39M–
Q1 FY2026Mar 31, 2026-$16.36M-160.8%
Q4 FY2025Dec 31, 2025-$14.71M–
Q3 FY2025Sep 30, 2025$2.21M–
Q2 FY2025Jun 30, 2025-$13.29M–
Q1 FY2025Mar 31, 2025$26.91M–
Q4 FY2024Dec 31, 2024-$38.88M–
Q3 FY2024Sep 30, 2024-$34.68M–
Q2 FY2024Jun 30, 2024-$39.81M-160.3%
Q1 FY2024Mar 31, 2024-$35.24M–
Q4 FY2023Dec 31, 2023-$47.50M–
Q3 FY2023Sep 30, 2023-$59.26M–
Q2 FY2023Jun 30, 2023$65.98M–
Q1 FY2023Mar 31, 2023-$76.58M–
Q4 FY2022Dec 31, 2022-$52.89M–
Q3 FY2022Sep 30, 2022-$59.58M-146.6%
Q2 FY2022Jun 30, 2022-$49.90M–
Q1 FY2022Mar 31, 2022-$66.45M–
Q4 FY2021Dec 31, 2021-$51.86M–
Q3 FY2021Sep 30, 2021$127.74M–
Q2 FY2021Jun 30, 2021-$39.70M–
Q1 FY2021Mar 31, 2021-$29.50M–
Q4 FY2020Dec 31, 2020-$17.93M–
Q3 FY2020Sep 30, 2020-$25.87M–
Q2 FY2020Jun 30, 2020-$25.57M–
Q1 FY2020Mar 31, 2020-$24.25M–
Q4 FY2019Dec 31, 2019-$14.05M-210.9%
Q3 FY2019Sep 30, 2019-$18.29M–
Q2 FY2019Jun 30, 2019-$11.79M–
Q1 FY2019Mar 31, 2019-$32.39M–
Q4 FY2018Dec 31, 2018$12.67M–
Q3 FY2018Sep 30, 2018-$23.08M–
Q2 FY2018Jun 30, 2018-$25.67M–
Q1 FY2018Mar 31, 2018-$26.76M–
Q4 FY2017Dec 31, 2017-$20.61M–
Q3 FY2017Sep 30, 2017-$3.61M–
Q2 FY2017Jun 30, 2017-$25.66M–
Q1 FY2017Mar 31, 2017-$25.65M–
Q4 FY2016Dec 31, 2016-$20.81M–
Q3 FY2016Sep 30, 2016-$11.37M–

More Seres Therapeutics figures

See a number that looks wrong?